anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS: Controversy remains as to whether the exercise stress test (EST) is sufficient for risk evaluation in patients with pre-excitation. This study aims to clarify the usefulness of EST in risk stratification in both asymptomatic and symptomatic patients presenting with pre-excitation.
METHODS AND RESULTS: This prospective study includes consecutive asymptomatic and symptomatic patients with pre-excitation referred for risk assessment. All participants performed an incremental EST (bicycle) prior to an electrophysiology study (EPS). Primary data from the EST included loss of pre-excitation during exercise, and primary data from the EPS included the measurement of accessory pathway effective refractory period (APERP), shortest pre-excited RR interval (SPERRI), and inducible arrhythmia with the use of a beta-adrenergic receptor agonist if deemed necessary. One hundred and sixty-four patients (59 asymptomatic, 105 symptomatic) completed an EST and EPS. Forty-five patients (27%) demonstrated low-risk findings on EST, of which 19 were asymptomatic and 26 were symptomatic. Six patients with low-risk EST findings had SPERRI/APERP ≤ 250 ms at EPS, and two of them were asymptomatic. The sensitivity, specificity, positive predictive value, negative predictive value (NPV), and accuracy of low-risk EST for excluding patients with SPERRI/APERP ≤ 250 ms were 40, 91, 87, 51, and 60%, respectively. The number of patients with inducible arrhythmia at EPS was similar in the asymptomatic (36, 69%) and symptomatic (73, 61%) groups.
CONCLUSION: Sudden loss of pre-excitation during EST has a low NPV in excluding high-risk APs. The EPS with the use of isoproterenol should be considered to accurately assess the risk of patients with pre-excitation regardless of symptoms (ClinicalTrials.gov Identifier: NCT03301935).
General Design and Methods. The underlying goal of this study is to assess 123-I MNI-308 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT. Approximately 10 patients with Alzheimers disease (AD) and 6 healthy controls (within +/- 2 years) will be recruited to participate in this study. Healthy controls will be examined to ensure that there is no evidence of neurodegenerative changes including cognitive decline.

An interval of at least 14 days will lapse between dosing in the first four AD subjects. This is intended to provide a longer period for AE assessments. Once complete, absent any serious adverse events in these initial AD subjects, dosing may commence with the remainder of the subjects, including healthy controls.

Informed consent will be obtained for all subjects. All subjects will undergo a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations. Subjects will be asked to undergo a bolus injection of 123-I MNI-308. Subjects will undergo serial SPECT imaging scans and serial venous plasma sampling for measurement of 123-I MNI-308 in plasma (both protein bound and free) over a period of up to 8 hours. The imaging analyses will be performed by an image-processing specialist who will remain masked to the procedures employed with each imaging acquisition. The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I MNI-308. Time to the peak uptake and amplitude of the peak uptake will be evaluated for all brain regions and the results for the AD patients and controls will be compared.
STUDY OBJECTIVES: To examine the risk of increased health care utilization (HU) linked to individual sleep disorders in children with chronic medical conditions.
METHODS: Medicaid claims data from a cohort of 16,325 children enrolled in the Coordinated Healthcare for Complex Kids (CHECK) project were used. Sleep disorders and chronic medical conditions were identified using International Classification of Diseases, Ninth, and 10th Revision, codes. Three HU groups were identified based on participants' prior hospitalizations and emergency department (ED) visits in the 12 months prior to enrollment: low (no hospitalization or ED visit), medium (1-2 hospitalizations or 1-3 ED visits), and high (≥ 3 hospitalizations or ≥ 4 ED visits). The odds of being in an increased HU group associated with specific sleep disorders after controlling for confounding factors were examined.
RESULTS: Children with chronic medical conditions and any sleep disorder had nearly twice the odds (odds ratio = 1.83; 95% confidence interval: 1.67-2.01) of being in an increased HU group compared with those without a sleep disorder. The odds of being in the increased HU group varied among sleep disorders. Only sleep-disordered breathing (odds ratio = 1.51; 95% confidence interval : 1.17-1.95), insomnia (odds ratio = 1.46; 95% confidence interval : 1.06-2.02), and circadian rhythm sleep disorder (odds ratio = 2.45; 95% confidence interval : 1.07-5.64) increased those odds. Younger age and being White were also linked to increased HU.
CONCLUSIONS: Sleep disorders are associated with increased risk of heightened HU (ED visits and/or hospitalizations) in children with chronic medical conditions. This risk varies by specific sleep disorders. These findings indicate the need for careful evaluation and management of sleep disorders in this high-risk cohort.
CITATION: Adavadkar PA, Brooks L, Pappalardo AA, Schwartz A, Rasinski K, Martin MA. Association between sleep disorders and health care utilization in children with chronic medical conditions: a Medicaid claims data analysis. J Clin Sleep Med. 2024;20(4):595-601.
Participants who join the trial will have have a control period (no intervention) of 3 to 12 months before receiving medication management service (MMS) at 8 NGO community pharmacies. Since there are 8 NGO community pharmacies, 2 NGO community pharmacies will start delivering MMS by phase at 3, 6, 9 and 12 month intervals. Therefore, all participants who join the trial will receive MMS by month 12 from recruitment date. During the MMS service, pharmacists will review the participants' medication history and conduct medication reconciliation, refer them to doctors for reviewing the prescribing decision if necessary, as well as provide education and lifestyle advice on medication management.
Abstract of the Disclosure Aqueous metal ammine siliconate solutions are the reaction product of selected metals or metal derivatives, selected mono-organosilicon materials, certain alkaline nitrogen compounds having the formula R-NH2, and water.          Amorphous materials are formed when volatiles are removed from the siliconate solutions.  The metal components in the resulting amorphous material are not readily leached out by normal weathering, washing or the like.  The solutions are useful in a method for treating substrates, such as wood, textiles, thread, canvas, carpeting, paper and masonry, to confer antimicrobial properties.  The organosilicon component can be selected so that the treatments also confer either hydrophobic or hydrophilic properties to the substrates.  The components of the solutions can be selected to enhance their ability to form continuous films of amorphous materials when used in such treatments, making the solutions useful to provide antimicrobial coatings which may be either hydrophobic or hydrophilic.  Such amorphous coatings are useful for applications such as wood preservation, masonry water repellents, marine varnishes and as treating agents to give a desirable hand to fabrics.  Powdered amorphous materials can be used to produce antimicrobial ointments.  The solutions are useful as hardeners for water-reducible resins and emulsions, including latex paints.  The solutions can be adapted to include components which may be slowly leachable from the resulting amorphous materials which can thus serve as a controlled-release binder to provide prolonged antimicrobial protection not only to the treated surfaces but also to their immediate surroundings.
Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands. With its numerous checkpoints, the incretin system seems to play a significant role in controlling glucose homeostasis and energy balance. The importance of the incretin hormones, namely the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), in controlling the function of adipose cells has been brought to light by recent studies. Notably, a "paradigm shift" in reevaluating the role of the incretin system in AT as a potential target to treat obesity-linked metabolic disorders resulted from the demonstration that a disruption of the GIP and GLP-1 signaling axis in fat is associated with adiposity-induced insulin-resistance (IR) and/or type 2 diabetes mellitus (T2D). We will briefly discuss the (patho)physiological functions of GLP-1 and GIP signaling in AT in this review, emphasizing their potential impacts on lipid storage, adipogenesis, glucose metabolism and inflammation. We will also address the conundrum with the perturbation of the incretin axis in white or brown fat tissue and the emergence of metabolic disorders. In order to reduce or avoid adiposity-related metabolic complications, we will finally go over a potential scientific rationale for suggesting AT as a novel target for GLP-1 and GIP receptor agonists and co-agonists.
BACKGROUND: Signal complexity (i.e. entropy) describes the level of order within a system. Low physiological signal complexity predicts unfavorable outcome in a variety of diseases and is assumed to reflect increased rigidity of the cardio/cerebrovascular system leading to (or reflecting) autoregulation failure. Aneurysmal subarachnoid hemorrhage (aSAH) is followed by a cascade of complex systemic and cerebral sequelae. In aSAH, the value of entropy has not been established yet.
METHODS: aSAH patients from 2 prospective cohorts (Zurich-derivation cohort, Aachen-validation cohort) were included. Multiscale Entropy (MSE) was estimated for arterial blood pressure, intracranial pressure, heart rate, and their derivatives, and compared to dichotomized (1-4 vs. 5-8) or ordinal outcome (GOSE-extended Glasgow Outcome Scale) at 12 months using uni- and multivariable (adjusted for age, World Federation of Neurological Surgeons grade, modified Fisher (mFisher) grade, delayed cerebral infarction), and ordinal methods (proportional odds logistic regression/sliding dichotomy). The multivariable logistic regression models were validated internally using bootstrapping and externally by assessing the calibration and discrimination.
RESULTS: A total of 330 (derivation: 241, validation: 89) aSAH patients were analyzed. Decreasing MSE was associated with a higher likelihood of unfavorable outcome independent of covariates and analysis method. The multivariable adjusted logistic regression models were well calibrated and only showed a slight decrease in discrimination when assessed in the validation cohort. The ordinal analysis revealed its effect to be linear. MSE remained valid when adjusting the outcome definition against the initial severity.
CONCLUSIONS: MSE metrics and thereby complexity of physiological signals are independent, internally and externally valid predictors of 12-month outcome. Incorporating high-frequency physiological data as part of clinical outcome prediction may enable precise, individualized outcome prediction. The results of this study warrant further investigation into the cause of the resulting complexity as well as its association to important and potentially preventable complications including vasospasm and delayed cerebral ischemia.
PROBLEM TO BE SOLVED: To provide an indole derivative exhibiting an NF-κB class II suppression action, and a method for producing the same.SOLUTION: An indole derivative is a derivative composed of 3-indole ethanol, gluconic acid and adipic acid. The production method is made of a process where the fruit of jujuba and a fermentation liquid obtained by adding Bacillus natto made of Natto Hompo to soybean powder are fermented with Monascus fungus. The obtained indole derivative shows an excellent effect of suppressing NF-κB class II, and suppresses inflammation and cancer. This is applied to cosmetics, food preparations and medicines. In the cosmetics, the NF-κB class II of skin cells is reduced, and it is effective for the control of wrinkles. Further, it guards plants from fungus and virus, and is utilized as a plant controller suppressing inflammation or a plant activator.SELECTED DRAWING: None
To assess the efficacy of the surgical procedure, pain scale evaluations were conducted on day 1,4 and 7, following the surgery. This evaluation involved a direct contact with the patients to gauge their subjective pain experience. A modified visual analog scale (VAS) was utilized, as described in reference \[34\]. No pain scale = 0, moderate pain scale = 5 and maximum pain scale = 10 \[21\]. In addition to efficacy measurements, safety measurements were also considered. The occurrence of adverse events (AEs) and serious adverse events (SAEs) was monitored throughout the duration of the study. These events were either detected by the investigator or reported by the patients themselves. The aim was to identify any potential complications or issues that arose because of the surgical procedure.
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of FLECTOR PATCH in patients with advanced renal disease. The renal effects of FLECTOR PATCH may hasten the progression of renal dysfunction in patients with pre-existing renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating FLECTOR PATCH. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of FLECTOR PATCH [see Drug Interactions (7)]. Avoid the use of FLECTOR PATCH in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If FLECTOR PATCH is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
PURPOSE: To obtain a mixed cathartic by blending a colon stimulating cathartic with lactic acid bacteria, rapidly recovering a patient to a normal state after suspension of administration, having slight fear of habituation even in chronic use. CONSTITUTION: This mixed cathartic is obtained by blending a colon stimulating cathartic [e.g. a diphenylmethane-based cathartic such as sodium picosulfate, etc., or an essence of DAIOU (rhizome of Pheum palmatum] with lactic acid bacteria (preferably Streptococcus faecalis, Lactobacillus acidophilus, etc.). The cathartic in an amount of one oral administration (e.g. 1-10mg in the case of sodium picosulfate) is mixed with 0.5-2g of a preparation of lactic acid bacteria preparation having >=10<7> live bacteria of lactic acid bacteria in 1g and is preferably administered. The cathartic may be mixed with lactic acid bacteria. When the cathartic is antibacterial, the cathartic and the lactic acid bacteria are separately packed or formed into a multi-layer tablet containing both in different layers by taking the influence of the cathartic on the lactic acid bacteria into consideration.
An orifice device for delivering one or more drugs includes an inner member having a proximal end and a distal end; and a winding helically wound around the inner member. The winding includes a plurality of distinct wires helically wound in parallel around the inner member. The winding and the inner member define at least three separate channels for carrying one or more drugs therethrough. An inlet is at the proximal end of the winding and an outlet is at the distal end of the winding for the plurality of distinct wires. In some embodiments, at least two of the plurality of distinct wires have a different dimension. An outer member is used over the winding. Also, at least two of the at least three separate channels have a different fluid flow rate. And, in some embodiments, at least two of the at least three separate channels carry a different drug.
Sarcopenia increases the risk of falls and fractures, as well as being related to various diseases and increased mortality. Different research groups propose different definitions that include the measurement of muscle mass by DXA and the assessment of hand grip strength through a hand dynamometer. However, these 2 instruments are not usually available in clinical practice. Our objective was to determine the diagnostic utility of 2 physical performance tests: gait speed and sit to stand test, as tools for the detection of patients with probable sarcopenia. A total of 706 women between 50 and 85 years of age were included and 376 of them completed the evaluation with the measurement of muscle mass. Anthropometric measurements were taken and physical performance was evaluated. We found that 26.1% registered a reduced gait speed while 55.3% presented alterations in performing the sit to stand test. The prevalence of sarcopenia ranged from 4.5% to 35% depending on the criteria used. Both tests showed a high negative predictive value (>70%) for the diagnosis of sarcopenia, while the sit to stand test also showed high sensitivity (>66%) for this diagnosis. We concluded that the implementation, in the clinical practice, of these easy and free tests would simplify the detection of patients with probable sarcopenia.
Rosacea is a chronic inflammatory skin disorder that can lead to fibrosis. However, the mechanisms underlying fibrosis in the later stages of rosacea have been less thoroughly investigated. Interleukin-17A (IL-17A) has been implicated in both inflammation and organ fibrosis; however, the effectiveness and mechanism of IL-17A-neutralizing antibodies in the later stages of rosacea-related fibrosis remain unclear. In this study, we induced rosacea-like lesions in mice using LL-37 and administered IL-17A-neutralizing antibodies. The results indicated that the IL-17A-neutralizing antibodies alleviated skin damage, reduced skin thickness, and decreased the secretion of inflammatory factors (TNF-α, CAMP, TLR4, P-NF-kB), angiogenesis-related factors (CD31, VEGF), and the TGF-β1 signaling pathway, along with factors associated with epithelial-mesenchymal transition and the deposition of fibrosis-related proteins (COL1) in the rosacea-like mouse models. Furthermore, the IL-17A-neutralizing antibodies effectively diminished the expression of IL-17, IL-17R, CXCL5, and CXCR2 in the skin. Our findings demonstrate that IL-17A-neutralizing antibodies inhibit the activation of the CXCL5/CXCR2 axis in rosacea-like skin tissue, thereby ameliorating inflammation and fibrosis associated with the condition.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to compounds of the formula (I)   and (II)   where R means hydrogen; R 1  means alkyl, amino-group or substituted amino-group; R 2  means optionally substituted phenyl; R 3  means hydrogen, halogen or optionally substituted alkyl; R 4  means hydrogen, optionally substituted alkyl, aryl or aralkyl. Synthesized compounds show analgetic, antiinflammatory activity and capability to inhibit leukotriene production, bone resorption and selective inhibition of COX-2 activity. Invention proposes also a pharmaceutical composition based on compounds said. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 17 cl, 130 ex, 13 tbl
FIELD: medicine, pharmacy. SUBSTANCE: medicinal form contains pharmaceutical gel-like composition involving an active component and thickening agent and placed in the dosing device. Thickening agent: xanthane resin, alkylcarboxyalkyl-, hydroxyalkyl-, hydroxyalkylalkylcellulose, cyclodextrins, polyglycol or acrylic polymer (0.2-5.0 wt.-%). An active component is dissolved, suspended or emulsified in composition. Composition can contain the special additions: sweetening substances, odor agents, stabilizing agents, solubilizing agents and dyes. Capacity of the dosing device is 20-150 ml, dosing compartment is 5 ml, not above, and has a pump for an active component extruding by one or two portions. EFFECT: improved method of preparing. 11 cl, 5 tbl
The invention relates to a nano traditional Chinese medicine for treating bronchial asthma and a preparation technology thereof. The medicine is prepared from the following raw materials containing effective ingredients in parts by weight: 8-16 parts of whiteflower hogfennel root, 10-20 parts of white peony root, 8-16 parts of cassia twig and 20-40 parts of milkvetch root. The production process thereof comprises the steps of ultrasonic wave smashing, extraction and dispersion, microwave extraction, supersonic speed spray drying smashing, nano grinding, mixing and capsule filling. The medicine in the invention lays stress on treating lung, spleen, kidney and liver with the same therapy as well as tonification and purgation in combination. The nano medicine lays stress on synergic and multi-target effects, has better treatment effect on patients suffering from bronchial asthma, and no toxic or side effect is produced. The medicine can be taken in four time periods respectively according to meridional flow and human blood flow laws. The medicine can be prepared into films to be pasted on local skin of human body and can be used for acupoint administration by transdermal absorption, thus the bronchial asthmais is treated.
BACKGROUND: Human infections due to Eubacterium are rare and knowledge of the condition is limited. This study aimed to describe clinical characteristics and outcome in patients with Eubacterium bacteremia.
METHODS: Episodes of Eubacterium bacteremia were identified through the clinical microbiology laboratory in Lund, Sweden. Medical records were retrospectively reviewed. Blood isolates of Eubacterium were collected and antibiotic susceptibility testing was performed with agar dilution.
RESULTS: Seventeen patients with Eubacterium bacteremia were identified of whom six had monomicrobial bacteremia. The incidence was 1.7 cases of Eubacterium bacteremia per million inhabitants and year. The median age was 67 years (interquartile range 63-79 years), and six patients had some form of malignancy. Most of the patients an abdominal focus of infection and the 30-day mortality was low (n = 1).
CONCLUSIONS: Invasive infections with Eubacterium have a low incidence. The condition has a low mortality and an abdominal focus of infection, and malignancy, is common.